Anti-Vitronectin V65 subunit, Polyclonal [pAb-V65]
Invented at University Of Bristol
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 153621 |
Applications | ELISA WB |
Antigen/Gene or Protein Targets | Vitronectin V65 subunit |
Synonyms | Complement S Protein antibody, Epibolin antibody, S Protein antibody, Serum Spreading Factor antibody, Somatomedin B antibody, Vitronectin V65 subunit antibody, VN antibody, VNT antibody, VTNC_HUMAN antibody |
Reactivity | Human |
Relevance | Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum. |
Host | Rabbit |
Immunogen | V65 peptide-carrier conjugate. The carrier protein is Keyhole Limpet Haemocyanin (KLH). |
Concentration | 1 mg/mL |
Formulation | PBS |
Method of Purification | Serum was first purified using Protein G and then a second affinity purification step was performed using the peptide antigen coupled to sepharose. |
Positive Control | Synthetic peptide |
Research Area | Cardiovascular, Immunology |
References: 2 entries
Ourradi et al. 2017. PLoS One. 12(7):e0181334. PMID: 28715494.
ELISA WB
Development and validation of novel biomarker assays for osteoarthritis.
Europe PMC ID: 28715494
Add a reference
References: 2 entries
Ourradi et al. 2017. PLoS One. 12(7):e0181334. PMID: 28715494.
ELISA WB
Development and validation of novel biomarker assays for osteoarthritis.
Add a reference